Avanir Pharmaceuticals Inc (NASDAQ:AVNR) was a big mover last session, as the company saw its shares rise by over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has now gained almost 59% since Apr 28. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) net profit margin is -86.70% and weekly performance is -13.74%. On last trading day company shares ended up $5.05. Analysts mean target price for the company is $9.25. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) distance from 50-day simple moving average (SMA50) is 2.87%.
On May 7, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the Bank of America Merrill Lynch 2014 Healthcare Conference on Tuesday, May 13, 2014 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time at the Encore at the Wynn in Las Vegas, NV. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares advanced 6.03% in last trading session and ended the day on $13.72. IRWD Gross Margin is 76.90% and its return on assets is -64.90%. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) quarterly performance is 1.63%.
Telik, Inc. (NASDAQ:TELK) soared after Monday’s announcement that the oncology drug development company had entered into a definitive merger agreement with privately held MabVax Therapeutics. Telik, Inc. (NASDAQ:TELK) shares moved down -1.68% in last trading session and was closed at $1.47, while trading in range of $1.34 – $1.56. Telik, Inc. (NASDAQ:TELK) year to date (YTD) performance is 23.53%.
NephroGenex Inc (NASDAQ:NRX) reported financial results for the quarter ended March 31, 2014. Net cash and cash equivalents as of March 31, 2014 were $33.5 million as compared to approximately $2.1 million as of December 31, 2013, reflecting the proceeds raised from the Company’s February IPO. Net Loss: NephroGenex reported a net loss of approximately $1.7 million, or $0.37 per common share, for the three months ended March 31, 2014 as compared to $474,000, or $1.48 per share for the three months ended March 31, 2013. NephroGenex Inc (NASDAQ:NRX) ended the last trading day at $5.28. Company weekly volatility is calculated as 14.78% and price to cash ratio as 233.64. NephroGenex Inc (NASDAQ:NRX) showed a negative weekly performance of -17.88%.
Leave a Reply